Halozyme Q1 revenue up 38% to $162M; GAAP EPS $0.29; reiterates 2023 guidance

HALOZYME THERAPEUTICS, INC.

2023-Q1 EPS reported $0.29 revenue$162,143,000

Revenue of $162.1M (+38% YoY); royalty revenue $99.6M (+43% YoY).
GAAP diluted EPS $0.29; non-GAAP diluted EPS $0.47 (flat YoY).
Q1 net income $39.6M vs $60.1M in Q1 2022; EBITDA $74.3M.
Reiterates 2023 guidance: total revenue $815-845M, non-GAAP EPS $2.50-$2.65.
Repurchased 4.2M shares for $150M in Q1; $275.6M cash end of quarter.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

HALOZYME THERAPEUTICS, INC. reported the first quarter ended March 31, 2023 results: revenue $162.1 million, net income $39.6 million, EPS $0.29. Guidance reaffirmed.

Period: the first quarter ended March 31, 2023
Revenue: $162.1 million
Net income: $39.6 million
EPS: $0.29
Guidance: reaffirmed
Result: reported results

Exact text from the filing

any general incorporation language in such filing. --- EX-99.1 (EX-99.1) --- HALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS Revenue Increased 38% YOY to $162.1 million; GAAP Diluted Earnings per Share of $0.29 and Non-GAAP Diluted Earnings per Share of $0.47 1 Royalty Revenue Increased 43% YOY to $99.6 million Reiterating 2023 Revenue Guidance

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

HALOZYME THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001159036-23-000037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.